MX388525B - Métodos mejorados para inactivación de enterovirus, composiciones de vacuna con adsorción de adyuvante y reducida en dosis obtenida de los mismos. - Google Patents

Métodos mejorados para inactivación de enterovirus, composiciones de vacuna con adsorción de adyuvante y reducida en dosis obtenida de los mismos.

Info

Publication number
MX388525B
MX388525B MX2017004534A MX2017004534A MX388525B MX 388525 B MX388525 B MX 388525B MX 2017004534 A MX2017004534 A MX 2017004534A MX 2017004534 A MX2017004534 A MX 2017004534A MX 388525 B MX388525 B MX 388525B
Authority
MX
Mexico
Prior art keywords
enterovirus
inactivation
improved methods
obtained therefrom
vaccine compositions
Prior art date
Application number
MX2017004534A
Other languages
English (en)
Spanish (es)
Other versions
MX2017004534A (es
Inventor
Jagdish Kamalaji Zade
Rajeev Mhalasakant Dhere
Rajendra Narayan Sabale
Sambhaji Shankar Pisal
Original Assignee
Serum Institute Of India Pvt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Serum Institute Of India Pvt Ltd filed Critical Serum Institute Of India Pvt Ltd
Publication of MX2017004534A publication Critical patent/MX2017004534A/es
Publication of MX388525B publication Critical patent/MX388525B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/125Picornaviridae, e.g. calicivirus
    • A61K39/13Poliovirus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04Inactivation or attenuation; Producing viral sub-units
    • C12N7/045Pseudoviral particles; Non infectious pseudovirions, e.g. genetically engineered
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04Inactivation or attenuation; Producing viral sub-units
    • C12N7/06Inactivation or attenuation by chemical treatment
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5252Virus inactivated (killed)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5254Virus avirulent or attenuated
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505Inorganic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/70Multivalent vaccine
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/32011Picornaviridae
    • C12N2770/32311Enterovirus
    • C12N2770/32334Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/32011Picornaviridae
    • C12N2770/32611Poliovirus
    • C12N2770/32634Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/32011Picornaviridae
    • C12N2770/32611Poliovirus
    • C12N2770/32661Methods of inactivation or attenuation
    • C12N2770/32663Methods of inactivation or attenuation by chemical treatment
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/32011Picornaviridae
    • C12N2770/32611Poliovirus
    • C12N2770/32671Demonstrated in vivo effect
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2017004534A 2014-10-07 2015-10-06 Métodos mejorados para inactivación de enterovirus, composiciones de vacuna con adsorción de adyuvante y reducida en dosis obtenida de los mismos. MX388525B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN3180MU2014 2014-10-07
PCT/IN2015/000376 WO2016063291A1 (en) 2014-10-07 2015-10-06 Improved methods for enterovirus inactivation, adjuvant adsorption and dose reduced vaccine compositions obtained thereof

Publications (2)

Publication Number Publication Date
MX2017004534A MX2017004534A (es) 2017-10-11
MX388525B true MX388525B (es) 2025-03-20

Family

ID=55300742

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017004534A MX388525B (es) 2014-10-07 2015-10-06 Métodos mejorados para inactivación de enterovirus, composiciones de vacuna con adsorción de adyuvante y reducida en dosis obtenida de los mismos.

Country Status (24)

Country Link
US (1) US10485862B2 (enExample)
EP (2) EP3204494B1 (enExample)
JP (2) JP6755243B2 (enExample)
KR (2) KR102510744B1 (enExample)
CN (2) CN113368227A (enExample)
AU (2) AU2015334495B2 (enExample)
CA (1) CA2963897C (enExample)
CU (1) CU24510B1 (enExample)
CY (1) CY1123078T1 (enExample)
DK (1) DK3204494T3 (enExample)
EA (1) EA201700187A1 (enExample)
ES (1) ES2803578T3 (enExample)
HU (1) HUE049104T2 (enExample)
LT (1) LT3204494T (enExample)
MX (1) MX388525B (enExample)
MY (1) MY204389A (enExample)
PE (1) PE20171132A1 (enExample)
PH (1) PH12017500627A1 (enExample)
PL (1) PL3204494T3 (enExample)
PT (1) PT3204494T (enExample)
SG (2) SG11201702838SA (enExample)
SI (1) SI3204494T1 (enExample)
UA (1) UA125788C2 (enExample)
WO (1) WO2016063291A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20171132A1 (es) * 2014-10-07 2017-08-09 Serum Inst Of India Private Ltd Metodos mejorados para la inactivacion de enterovirus y la adsorcion sobre coadyuvantes, y composiciones de vacunas con dosis reducidas obtenidas de estos
WO2017197034A1 (en) 2016-05-10 2017-11-16 Najit Technologies, Inc. Inorganic polyatomic oxyanions for protecting against antigenic damage during pathogen inactivation for vaccine production
SG11201900365WA (en) * 2016-08-26 2019-02-27 Serum Institute Of India Pvt Ltd Multivalent vaccine composition
TWI711700B (zh) * 2017-07-10 2020-12-01 印度商印度血清研究公司 使腸病毒去活化之改良方法、佐劑吸附及所獲得之劑量減少的疫苗組成物
US11648304B2 (en) 2017-11-03 2023-05-16 Takeda Vaccines, Inc. Zika vaccines and immunogenic compositions, and methods of using the same
KR20200090893A (ko) 2017-11-30 2020-07-29 다케다 백신즈 인코포레이티드 지카 바이러스를 비활성화시키기 위한 방법, 및 관련 방법들
SG11202007503WA (en) 2018-02-07 2020-09-29 Bharat Biotech Int Ltd A process for enterovirus purification and inactivation and vaccine compositions obtained thereof
CN109550046B (zh) * 2018-12-21 2020-08-25 北京民海生物科技有限公司 一种吸附无细胞百白破-脊髓灰质炎-b型流感嗜血杆菌联合疫苗及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR199802783T2 (xx) * 1996-07-02 1999-03-22 Connaught Laboratories Limited �ok de�erli DTP polyo a��lar.
MX2007002372A (es) * 2004-08-27 2007-05-08 Panacea Biotec Ltd Vacuna para la poliomielitis inactivada derivada de la cepa sabin del virus de la polio.
CN1647822A (zh) * 2005-02-06 2005-08-03 北京生物制品研究所 脊髓灰质炎灭活疫苗及其制备方法
CN103357003A (zh) * 2006-09-07 2013-10-23 葛兰素史密丝克莱恩生物有限公司 疫苗
CN100540662C (zh) * 2006-12-06 2009-09-16 云南沃森生物技术有限公司 一种混合床凝胶过滤层析技术用于病毒性疫苗纯化的方法
WO2010036226A1 (en) * 2008-09-26 2010-04-01 George Nelson Process for treatment of rheumatoid arthritis, tremors/parkinson's disease and multiple sclerosis
CN102655879B (zh) * 2009-12-16 2016-03-09 印度血清研究所 疫苗组合物
US20140112950A1 (en) * 2011-03-02 2014-04-24 Manmohan Singh Combination vaccines with lower doses of antigen and/or adjuvant
GB201105981D0 (en) * 2011-04-08 2011-05-18 Glaxosmithkline Biolog Sa Novel process
PE20171132A1 (es) * 2014-10-07 2017-08-09 Serum Inst Of India Private Ltd Metodos mejorados para la inactivacion de enterovirus y la adsorcion sobre coadyuvantes, y composiciones de vacunas con dosis reducidas obtenidas de estos

Also Published As

Publication number Publication date
MY204389A (en) 2024-08-27
EA201700187A1 (ru) 2017-12-29
CU24510B1 (es) 2021-05-12
CU20170044A7 (es) 2018-09-05
PH12017500627A1 (en) 2017-09-25
JP2017533899A (ja) 2017-11-16
AU2021269395A1 (en) 2021-12-16
CY1123078T1 (el) 2021-10-29
AU2015334495B2 (en) 2021-08-19
SI3204494T1 (sl) 2020-08-31
JP7063957B2 (ja) 2022-05-09
JP6755243B2 (ja) 2020-09-16
JP2020203906A (ja) 2020-12-24
CA2963897C (en) 2023-08-22
KR20170063947A (ko) 2017-06-08
PE20171132A1 (es) 2017-08-09
EP3204494B1 (en) 2020-04-01
ES2803578T3 (es) 2021-01-28
US10485862B2 (en) 2019-11-26
SG11201702838SA (en) 2017-05-30
US20170348411A1 (en) 2017-12-07
PT3204494T (pt) 2020-07-10
CA2963897A1 (en) 2016-04-28
EP3204494A1 (en) 2017-08-16
CN106999569B (zh) 2021-06-29
BR112017007089A2 (pt) 2017-12-26
NZ731341A (en) 2023-11-24
CN113368227A (zh) 2021-09-10
LT3204494T (lt) 2020-07-10
AU2015334495A1 (en) 2017-05-25
KR102510744B1 (ko) 2023-03-15
WO2016063291A1 (en) 2016-04-28
HUE049104T2 (hu) 2020-08-28
PL3204494T3 (pl) 2020-09-21
CN106999569A (zh) 2017-08-01
EP3663396A1 (en) 2020-06-10
SG10202010814RA (en) 2020-12-30
MX2017004534A (es) 2017-10-11
AU2021269395B2 (en) 2024-05-23
UA125788C2 (uk) 2022-06-08
KR20210021148A (ko) 2021-02-24
KR102219638B1 (ko) 2021-02-23
DK3204494T3 (da) 2020-07-06

Similar Documents

Publication Publication Date Title
MX388525B (es) Métodos mejorados para inactivación de enterovirus, composiciones de vacuna con adsorción de adyuvante y reducida en dosis obtenida de los mismos.
CO2017002170A2 (es) Terapia de combinación para tratar un paramixovirus
EA201791460A1 (ru) N4-гидроксицитидин и связанные с ним производные и варианты противовирусного применения
EA201790630A1 (ru) Способы получения рибозидов
MX2018012880A (es) Metodos para proporcionar arn de hebra sencilla.
PH12017500207A1 (en) Indoles for use in influenza virus infection
EA201792613A1 (ru) Модуляторы cot и способы их применения
EA201692219A1 (ru) Способы получения противовирусных соединений
EA201692512A1 (ru) Способы и композиции для лечения синтетическими наноносителями и ингибиторами иммунной контрольной точки
PH12017500393A1 (en) Pyrrolopyrimidines for use in influenza virus infection
CR20180213A (es) Derivados de indol mono -o- disustituidos como inhibidores de la replicación viral del dengue
HUE042628T2 (hu) Mono- vagy diszubsztituált indolok mint dengue vírus replikáció inhibitorok
MX2021010060A (es) Produccion de virus en huevos aviares.
MX376962B (es) Nuevos compuestos macrociclicos.
MX379510B (es) Coronavirus bovino atenuado y vacunas relacionadas.
EA201790517A1 (ru) Способы и композиции для индуцирования защитного иммунитета против филовирусной инфекции
MX2017000142A (es) Celulas estromales mesenquimatosas para tratar el sindrome de respuesta inflamatoria sistemica.
IN2014MU00455A (enExample)
CL2016000300A1 (es) Métodos terapéuticos
PH12020550204A1 (en) A non-naturally occurring porcine reproductive and respiratory syndrome virus (prrsv) and methods of using
EA201691638A1 (ru) Новые способы индуцирования иммунного ответа
MX2018014977A (es) Composiciones y metodos para formulaciones de alfavirus vivos atenuados.
MX2018014955A (es) Vacunas atenuadas vivas del virus de la influenza equina.
CL2018000253A1 (es) Respuesta inmunitaria potenciada de las especies porcinas
UY34840A (es) Vacuna de virus de schmallenberg (sbv), métodos de producción y sus usos